FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24731-500E	SERIAL NO. 09/127,138
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GRUENBERG	
	FILING DATE 7/31/98	GROUP 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
BS	A	5	1	8	8	9	6	9	02/23/93	Arai et al	436	548	06/15/89

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes	Translation No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED
	5/1/2002

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24731-500E	SERIAL NO. 09/127,138
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GRUENBERG	
	FILING DATE 7/31/98	GROUP ~~1643~~ 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
RB		5	8	5	8	3	5	8	01/12/99	June et al	424	130.1	06/03/94

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes	Translation No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED 5/1/2002

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24731-500E	SERIAL NO. 09/127,138
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GRUENBERG	
	FILING DATE 7/31/98	GROUP ~~1643~~ 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
PSG	AA	3	8	2	1	0	8	7	6/28/74	Knazek *et al.*	195	127	5/18/72
	AB	3	8	8	3	3	9	3	5/13/75	Knazek *et al.*	195	1.8	2/11/74
	AC	3	9	9	7	3	9	6	12/14/76	Delente	195	1.8	7/02/73
	AD	4	0	8	7	3	2	7	5/02/78	Feder *et al.*	195	1.7	4/12/76
	AE	4	2	0	0	6	8	9	4/29/80	Knazek *et al.*	435	2	8/29/78
	AF	4	2	0	6	0	1	5	6/03/80	Knazek *et al.*	435	2	8/29/78
	AG	4	2	2	0	7	2	5	09/02/80	Knazek *et al.*	435	285	4/03/78
	AH	4	3	0	1	2	4	9	11/17/81	Markus *et al.*	435	235	7/23/80
	AI	4	3	9	1	9	1	2	7/5/83	Yoshida *et al.*	435	241	9/18/80
	AJ	4	5	4	6	0	8	3	10/08/85	Meyers *et al.*	435	240	4/22/83
	AK	4	6	2	9	6	8	6	12/16/86	Gruenberg	435	1	06/14/82
	AL	4	6	9	0	9	1	5	09/01/87	Rosenberg	514	2	08/08/85
	AM	4	7	2	2	9	0	2	02/02/88	Harm *et al.*	435	284	11/04/85
	AN	4	8	0	4	6	2	8	02/14/89	Cracauer *et al.*	435	240.242	08/19/87
	AO	4	8	0	8	1	5	1	02/28/89	Dunn, Jr. *et al.*	604	6	04/27/87
	AP	4	8	4	9	3	2	9	07/18/89	Leung *et al.*	435	2	04/20/87
	AQ	4	8	6	1	5	8	9	08/29/89	Ju	424	93	03/23/87
	AR	4	8	9	4	3	4	2	01/16/90	Guinn *et al.*	435	291	09/22/86
	AS	4	9	3	7	0	7	1	06/26/90	Cioco *et al.*	424	85.2	12/29/87
	AT	4	9	7	1	7	9	5	11/20/90	Longenecker *et al.*	424	93	07/21/88
	AU	4	9	7	3	5	5	8	11/27/90	Wilson *et al.*	435	240.242	04/28/88
	AV	4	9	9	9	2	9	8	03/12/91	Wolfe *et al.*	435	240.242	04/27/88
	AW	5	0	0	2	8	7	9	03/26/91	Bowlin *et al.*	435	71.1	12/05/89
	AX	5	0	1	5	5	8	5	05/14/91	Robinson	435	240.242	02/23/88
	AY	5	0	4	1	2	8	9	08/20/91	Phillips *et al.*	424	85.2	11/13/87

EXAMINER	DATE CONSIDERED 5/1/2002

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24731-500E	SERIAL NO. 09/127,138
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GRUENBERG	
	FILING DATE 7/31/98	GROUP 1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
RBS	AZ	5	0	5	7	4	2	3	10/15/91	Hiserodt *et al.*	435	240.23	12/18/87
	BA	5	0	6	1	6	2	0	10/29/91	Tsukamoto *et al.*	435	7.21	03/30/90
	BB	5	0	6	4	7	6	4	11/12/91	Besnainon *et al.*	435	285	12/19/89
	BC	5	1	2	6	1	3	2	06/30/92	Rosenberg	424	93	08/21/89
	BD	5	1	2	6	2	3	8	06/30/92	Gebhard *et al.*	435	3	02/15/90
	BE	5	1	4	7	2	8	9	09/15/92	Edelson	604	4	03/29/90
	BF	5	1	4	7	7	8	4	09/15/92	Peault	435	7.24	04/12/90
	BG	5	1	6	2	2	2	5	11/10/92	Sager *et al.*	435	240.243	07/15/91
	BH	5	1	9	2	5	3	7	03/09/93	Osband	424	85.2	08/19/91
	BI	5	2	0	2	2	5	4	04/13/93	Amiot *et al.*	435	240.242	10/11/90
	BJ	5	2	2	9	1	1	5	07/20/93	Lynch	424	93	07/26/90
	BK	5	2	4	2	6	8	7	09/07/93	Tykocinski *et al.*	424	93	04/25/91
	BL	5	2	7	7	9	0	7	01/11/94	Loria	424	93	07/24/92
	BM	5	3	1	6	7	6	3	05/31/94	Ochoa *et al.*	424	85.2	07/10/92
	BN	5	3	2	6	7	6	3	07/05/94	Gluchowski *et al.*	514	249	01/29/93
	BO	5	3	7	4	5	4	9	12/20/94	Leung	435	240.2	01/31/91
	BP	5	3	9	9	3	4	6	03/21/95	Anderson *et al.*	424	93.21	03/30/94
	BQ	5	3	9	9	3	4	7	03/21/95	Trentham *et al.*	424	184.1	09/25/92
	BR	5	4	0	9	8	1	3	04/24/95	Schwartz	435	7.24	09/30/93
	BS	5	4	1	1	7	4	9	05/02/95	Mayo *et al.*	424	578	12/23/92
	BT	5	4	3	7	9	9	4	08/01/95	Emerson *et al.*	435	240.2	12/10/93
	BU	5	4	4	3	9	8	3	08/22/95	Ochoa *et al.*	435	240.2	03/21/88
	BV	5	4	5	9	0	6	9	10/17/95	Palsson *et al.*	435	289.1	01/06/94
	BW	5	4	6	6	5	7	2	11/14/95	Sasaki *et al.*	435	2	04/25/94
	BX	5	4	7	0	7	3	0	11/28/95	Greenberg *et al.*	435	172.3	08/08/94

EXAMINER	DATE CONSIDERED 5/1/2002

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24731-500E	SERIAL NO. 09/127,138
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GRUENBERG	
	FILING DATE 7/31/98	GROUP 1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
MBJ	BY	5	4	7	6	9	9	7	12/19/95	Kaneshima *et al.*	800	2	05/17/94
	BZ	5	4	9	8	5	3	7	03/12/96	Bresler *et al.*	435	235.1	03/09/94
	CA	5	5	1	2	4	4	4	04/30/96	Patard *et al.*	435	6	11/30/94
	CB	5	5	9	9	7	0	5	02/04/97	Cameron	435	378	11/16/93
	CC	5	6	0	5	8	2	2	02/25/97	Emerson *et al.*	435	172.3	12/01/94
	CD	5	6	2	2	8	5	7	04/22/97	Goffe	435	378	08/08/95
	CE	5	6	2	7	0	7	0	05/06/97	Gruenberg	435	786.5	07/26/95
	CF	5	6	3	5	3	8	6	06/03/97	Palsson *et al.*	435	372	11/02/94
	CG	5	6	3	5	3	8	7	06/03/97	Fei *et al.*	435	378	04/03/95
	CH	5	6	4	6	0	4	3	07/08/97	Emerson *et al.*	435	373	03/10/95
	CI	5	6	5	6	4	2	1	08/12/97	Gebhard *et al.*	435	3	02/12/91
	CJ	5	6	7	6	8	4	9	10/14/97	Sammons *et al.*	210	806	03/08/95
	CK	5	7	1	8	8	8	3	02/17/98	Harlan *et al.*	424	9.2	02/17/94
	CL	5	7	2	8	5	8	1	03/17/98	Schwartz *et al.*	435	385	06/07/95
	CM	5	7	6	3	2	6	1	06/09/98	Gruenberg	435	286.5	12/05/96
	CN	5	7	6	3	2	6	6	06/09/98	Palsson *et al.*	435	289.1	11/07/94
	CO	5	8	1	1	3	0	1	09/22/98	Cameron	435	372	08/07/96

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes	Translation No
MBJ	CP	0	4	0	5	9	7	2	1/2/91	EPO	~~A1~~	—		
	CQ	9	0	0	5	5	4	1	05/31/90	PCT	—	—		
	CR	9	0	1	5	8	7	7	12/27/90	PCT	—	—		
	CS	9	1	0	4	3	1	7	04/04/91	PCT	—			

EXAMINER	DATE CONSIDERED 5/1/2002

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24731-500E	SERIAL NO. 09/127,138
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GRUENBERG	
	FILING DATE 7/31/98	GROUP 1643

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes	Translation No
BS	CT	9	1	1	8	9	7	2	12/12/91	PCT				
	CU	9	3	1	9	7	6	7	10/14/93	PCT				
	CV	9	4	2	2	4	8	9	10/13/94	PCT				
	CW	9	4	2	3	7	6	0	10/27/94	PCT				
	CX	9	4	2	8	9	1	2	12/22/94	PCT				
	CY	9	4	2	9	4	3	6	12/22/94	PCT				
	CZ	9	5	2	9	6	7	3	11/09/95	PCT				
	DA	9	5	3	3	8	2	3	12/14/95	PCT				
	DB	9	5	3	3	8	2	3	12/14/95	PCT				
	DC	9	6	3	4	9	5	6	11/07/96	PCT				
	DD	9	6	3	4	9	7	0	11/7/96	PCT				
	DE	9	6	4	0	8	6	0	12/19/96	PCT				
	DF	9	6	4	0	8	7	6	12/19/96	PCT				
	DG	9	7	0	5	2	3	9	2/13/97	PCT				
	DH	9	7	3	1	6	4	7	09/04/97	PCT				
	DI	9	8	2	5	4	5	7	06/18/98	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DJ	Alberts, B. *et al.*, "Molecular Biology of the Cell", 3rd ed., Garland Publishing, Inc., ppp. 1169 (1994)
DK	Autran *et al.*, A ThO/Th2-like function of $CD4^{+}CD7^{-}$ T helper cells from normal donors and HIV-infected patients, J. Immunol. 154: 1408-1417 (1995)
DL	Bartholeyns *et al.*, Immune control of neoplasia by adoptive transfer of macrophages: Potentiality for antigen presentation and gene transfer, Anticancer Research 14: 2673-2676 (1994)

EXAMINER	DATE CONSIDERED 5/1/2001

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24731-500E	SERIAL NO. 09/127,138
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GRUENBERG	
	FILING DATE 7/31/98	GROUP 1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

VPBS	DM	Benvenuto *et al.*, Enhanced production of interferon-γ by T lymphocytes cloned from rejected kidney grafts, Transplantation 51: 887-890 (1991)
	DN	Benveuto *et al.*, Tumor necrosis factor-alpha synthesis by cerebrospinal-fluid-derived T cell clones from patients with multiple sclerosis, Clin. Exp. Immunol. 84: 97-102 (1991)
	DO	Bernhard *et al.*, Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood, Cancer Res. 55: 1099-1104 (1995)
	DP	Boiardi *et al.*, Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-Lak) in recurrent glioblastoma patients, Cancer Immunol. Immunother. 39: 193-197 (1994)
	DQ	Brod *et al.*, Restricted T cell expression of IL-2/Ifn-γ mRNA in human inflammatory disease, J. Immunol. 147: 810-815 (1991)
	DR	Cesano *et al.*, Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach, J. Clin. Invest. 94: 1076-1084 (1994)
	DS	Chen *et al.*, Donor T cells can be induced to grow and survive long term *in vivo* without previous host immunosuppression, J. Immunol. 152: 4767-4774 (1994)
	DT	Chen *et al.*, Regulatory T cell clone induced by oral tolerance: Suppression of autoimmune encephalomyelitis, Science 265: 1237-1240 (1994)
	DU	Cherwinski *et al.*, Two types of mouse helper T cell clone, J. Exp. Med. 166: 1229-1244 (1987)
	DV	Chick *et al.*, Beta cell culture on synthetic capillaries: An artificial endocrine pancreas, Science 187: 847-849 (1975)
	DW	Clerici *et al.*, A T_H1-T_H2 switch is a critical step in the etiology of HIV infection, Immunology Today 14.3: 107-111 (1993)
	DX	David *et al.*, Continuous production of carcinoembryonic antigen in hollow giber cell culture units: Brief communication, J. Natl. Cancer Inst. 60.2: 303-306 (Feb. 1978)
	DY	Davis, J.E. *et al.*, "Mass Transfer Between Capillary Blood and Tissues", Chem. Eng. J., 7:213-225 (1974)
	DZ	de Carli *et al.*, Cytolytic T cells with Th1- like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy, J. Clini. Endocrinol. Metabol. 77.5: 1120-1124 (1993)
✓	EA	De Jong *et al.*, Maturation- and differentiation-dependent responsiveness of human $CD4^+$ T helper subsets, J. Immunol. 149: 2795-2802 (Oct. 1992)

EXAMINER	DATE CONSIDERED 5/1/2002

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24731-500E	SERIAL NO. 09/127,138
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GRUENBERG	
	FILING DATE 7/31/98	GROUP 1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	EB	Del Prete *et al.*, High potential to tumor necrosis factor *x* (TNF-*x*) production of thyroid infiltrating T lymphocytes in Hashimoto's thyroiditis: A peculiar feature of destructive thyroid autoimmunity, Autoimmunity 4: 267-276 (1989)
	EC	Del Prete *et al.*, Purified Protein derivative of *Mycobacterium tuberculosis* and excretory-secretory antigen(s) of *Toxocara canis* expand *in vitro* human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production, J. Clin. Invest. 88: 346-350 (July 1991)
	ED	Dillman *et al.*, Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma, Cancer 68: 1-8 (1991)
	EE	Dillman *et al.*, Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: A national biotherapy study group trial, J. Clin. Oncology 9.7: 1233-1240 (1991)
	EF	Eastcott *et al.*, Adoptive transfer of cloned T helper cells ameliorates periodontal disease in nude rats, Oral Microbiol. Immunol. 9: 284-289 (1994)
	EG	Elson *et al.*, T cell subpopulation phenotypes in filarial infections: CD27 negativity defines a population greatly enriched for T_h2 cells, Internat. Immunol. 6: 1003-1009 (1993)
	EH	Englemann *et al.*, Activation of human T lymphocyte subsets: Helper and suppressor/cytotoxic T cells recognize and respond to distinct histocompatibility antigens, J. Immunol. 127: 2124-2129 (1981)
	EI	Faradji *et al.*, Large scale isolation of human blood monocytes by continuous flow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients, J. Immunol. Meth. 174: 297-309 (1994)
	EJ	Fiorentiono *et al.*, Two types of mouse T helper cell, J. Exp. Med. 170: 2081-2095 (1989)
	EK	Firestein *et al.*, A new murine $CD4^+$ T cell subset with an unrestricted cytokine profile, J. Immunol. 143: 518-525 (1989)
	EL	Foon *et al.*, Renal cell carcinoma treated with continuous-infusion interleukin-2 with *ex vivo*-activated killer cells, J. Immunotherapy 11: 184-190 (1992)
	EM	Foulis *et al.*, Insulitis in type 1 (insulin-dependent) diabetes mellitus in Man-macrophages, lymphocytes, and interferon-μ containing cells, J. Pathol. 165: 97-103 (1991)
	EN	Fowell *et al.*, Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the $CD4^+$ T cell subset that inhibits this autoimmune potential, J. Exp. Med. 177: 627-636 (1993)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 24731-500E	SERIAL NO. 09/127,138
APPLICANT GRUENBERG	
FILING DATE 7/31/98	GROUP 1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	EO	Fowler *et al.*, Donor lymphoid cells of Th2 cytokine phenotype reduce lethal graft versus host disease and facilitate fully allogeneic cell transfers in sublethally irradiated mice, Advances in Bone Marrow Purging and Processing: Fourth International Symposium, 533-540 (1994)
	EP	Freedman *et al.*, Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: A pilot trial, J. Immunol. 16: 198-210 (1994)
	EQ	Galandrini *et al.*, Antibodies to CD44 trigger effector functions of human T cell clones, J. Immunol. 150: 4225-4235 (1993)
	ER	Gaudernack *et al.*, Isolation of pure functionally active $CD8^+$ T cells positive selection with monoclonal antibodies directly conjugated to monosized magnetic microspheres, J. Immun. Meth. 90: 179-187 (1986)
	ES	Goedegbuure *et al.*, Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study, J. Clin. Oncol. 13: 1939-1949 (1995)
	ET	Gold *et al.*, Adoptive Tumor immunotherapy using human $CD4^+$ T-cells, Br. J. Cancer 67: 865 (1993)
	EU	Gold *et al.*, Autolymphocyte therapy, J. Surgical Res. 59: 270-286 (1995)
	EV	Grabbe *et al.*, Dendritic cells as initiators of tumor immune responses: A Possible strategy for tumor immunotherapy, Immunology Today 16: 117-121 (1995)
	EW	Graham *et al.*, The use of *ex vivo*-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study, Seminars in Urology 11: 27-34 (1993)
	EX	Grau *et al.*, Implications of cytokines in immunopathology: Experimental and clinical data, Eur. Cytokine Net. 1: 203-210 (1990)
	EY	Grimm *et al.*, Lymphyokine-activated killer cell phenomenon, J. Exp. Med. 155: 1823-1841 (1982)
	EZ	Gullino *et al.*, Tissue culture on artificial capillaries, Meth. Enzymol. 58: 178-184 (1979)
	FA	Hager *et al.*, Tumor-associated antigens produced by mouse mammary tumor cells in artificial capillary culture, J. Natl. Cancer Inst. 69: 1359-1365 (1982)
↓	FB	Hammel *et al.*, Effect of interleukin-1α on the *in vitro* activation of tumor-draining lymph node cells for adoptive immunotherapy, J. Immunotherapy 16: 1-12 (1993)

EXAMINER	DATE CONSIDERED 5/1/2001

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24731-500E	SERIAL NO. 09/127,138
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GRUENBERG	
	FILING DATE 7/31/98	GROUP 1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

VB5	FC	Hansen *et al.*, Monoclonal antibodies identifying a novel T-cell antigen and Ia antigen of human lymphocytes, Immunogenetics 10: 247-260 (1980)
	FD	Hara *et al.*, Human T cell activation, J. Exp. Med. 161: 1513-1524 (1985)
	FE	Henschler *et al.*, Maintenance of transplantation potential in *ex vivo* expanded $CD34^+$ - selected human peripheral blood progenitor cells, Blood 84: 2898-2903 (1994)
	FF	Herberman *et al.*, Adoptive therapy with purified CD8 cells in HIV infection, AIDS/Cancer Therapies, 35-44.
	FG	Ho *et al.*, A phase 1 study of adoptive transfer of autologous $CD8^+$ lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS, Blood 81: 2093-2101 (1993)
	FH	Hsieh *et al.*, Differential regulation of T helper phenotype development by interleukins 4 and 10 in an *αβ* T-cell-receptor transgenic system, Proc. Natl. Acad. Sci. USA 89: 6065-6089 (1992).
	FI	Huet *et al.*, T cell activation via CD2 [T, gp50]: The role of accessory cells in activating resting T cells via CD2, J. Immunol. 137: 1420-1428 (1986)
	FJ	Igletseme *et al.*, Resolution of murine chlamydial genital infection by the adoptive transfer of a biovar-specific, TH_1 Lymphocyte clone, Regional Immunology 5: 317-324 (1993)
	FK	Jensen *et al.*, Production of anchorage-dependent cells-problems and their possible solutions, Biotechnol. Bioeng. 23: 2703-2716 (1981)
	FL	Klimas *et al.*, Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin-2 infusion, AIDS 8: 1073-1081 (1994)
	FM	Knazek *et al.*, Cell culture on artificial capillaries: An approach to tissue growth *in vitro*, Science 173: 65-67 (1972)
	FN	Knazek *et al.*, Hormone production by cells grown in vitro on artificial capillaries, Exp. Cell Res. 84: 251-254 (1974)
	FO	Knazek *et al.*, Brief communication: Formation of solid human mammary carcinoma *in vitro*, J. Natl. Cancer Inst. 58: 419-422 (1977)
	FP	Koretz *et al.*, Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer, Arch. Surg. 126: 898-903 (1991)

EXAMINER	DATE CONSIDERED 5/11/2000

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24731-500E	SERIAL NO. 09/127,138
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GRUENBERG	
	FILING DATE 7/31/98	GROUP 1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	FQ	Lane *et al.*, Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation, Blood 85: 275-282 (1995)
	FR	Lea *et al.*, Characterization of human mononuclear cells after positive selection with immunomagnetic particles, Scand. J. Immunol. 23: 509-519 (1986)
	FS	Lea *et al.*, Magnetic Monosized polymer particles for fast and specific fractionation of human mononuclear cells, Scan. J. Immunol. 22: 207-216 (1985)
	FT	Ledbetter *et al.*, Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells, J. Immunol. 135: 2331-2336 (1985)
	FU	Ledbetter *et al.*, Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression, J. Immunol. 135: 1819-1825 (1985)
	FV	Ledbetter *et al.*, Signal transduction through CD4 receptors: Stimulatory vs. inhibitory activity is regulated by CD4 proximity to the CD3/T cell receptor, Eur. J. Immunol. 18: 525-532 (1988)
	FW	Liblau *et al.*, Th1 and Th2 $CD4^+$ T Cells in the pathogenesis of organ-specific autoimmune diseases, Immunology Today 16: 34-38 (1995)
	FX	Lindqvist *et al.*, Enhanced IL-4-mediated D10.G4.1 Proliferation with suboptimal concentrations of anti-IL-4 receptor Monoclonal antibodies, J. Immunol. 150: 394-398 (1993)
	FY	Lum *et al.*, In vitro regulation of immunoglobulin synthesis by T-cell subpopulations defined by a new human T-cell antigen, Cell. Immunol. 72: 122-129 (1982)
	FZ	Luyten *et al.*, Purification and partial amino acid sequence of osteogenin, a protein initiating bone differentiation, J. Biol. Chem. 264(23):13377-13380 (1989)
	GA	Lynch *et al.*, Interleukin 7 promotes long-term *in vitro* growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy *in vivo*, J. Exp. Med. 179: 31-42 (1994)
	GB	Manetti *et al.*, CD30 expression by $CD8^+$ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+$CD30^+$ T cell clones in human immunodeficiency virus infection, J. Exp. Med. 180: 2407-2411 (1994)
	GC	Manger *et al.*, T cell activation: Differences in the signals required for IL 2 Production by nonactivated and activated T cells, J. Immunol. 135: 3669-3673 (1985)
	GD	Marcus *et al.*, The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced *in vivo* antitumor activity, J. Immunotherapy 15: 105-112 (1994)

EXAMINER	DATE CONSIDERED 5/11

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24731-500E	SERIAL NO. 09/127,138
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GRUENBERG	
	FILING DATE 7/31/98	GROUP 1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

PAS	GE	Mastsumura *et al.*, Characteristics and *in vivo* homing of long-term T-cell Lines and clones derived from tumor-draining lymph nodes, Cancer Res. 54: 2744-2750 (1994)
	GF	Miller *et al.*, Large scale *ex vivo* expansion and activation of human natural killer cells for autologous therapy, Bone Marrow Transplantation 14: 555-562 (1994)
	GG	Mosmann *et al.*, TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties, Ann. Rev. Immunology 7: 145-173 (1989)
	GH	Mosmann *et al.*, The expanding universe of T-cell subset: Th1, Th2 and more, Immunology Today (March 1996).
	GI	Mosmann *et al.*, Two types of murine helper T cell clone, J. Immunol. 136: 2348-2357 (1986)
	GJ	Mulder *et al.*, Culture of tumor-infiltrating lymphocytes from melanoma and colon carcinoma: Removal of tumor cells does not affect tumor-specificity, Cancer Immunol. Immunother. 41: 293-301 (1995)
	GK	Nagler *et al.*, Red blood cell depletion and enrichment of $CD34^+$ Hematopoietic progenitor cells from human umbilical cord blood using soybean agglutinin and CD34 immunoselection, Exp. Hematol. 22: 1134-1140 (1994)
	GL	Nakajima *et al.*, Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression, Proc. Natl. Acad. Sci. USA 91: 7889-7893 (1994)
	GM	Niessner *et al.*, Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR), Clin. Exp. Immunol. 101: 428-435 (1995)
	GN	O'Garra *et al.*, Role of cytokines in determining T-lymphocyte function, Immunology 6: 458-466 (1994)
	GO	Ohno *et al.*, Lectin-activated Killer cells rapidly induced by pokeweed mitogen conjugated beads and their *in vivo* antitumor effects, Int. J. Immunopharmacol. 16: 761-768 (1994)
	GP	Okamoto *et al.*, The antitumor effect of tumor-draining lymph node cells activated by both anti-CD3 monoclonal antibody and activated B cells as costimulatory-signal-providing cells, Cancer Immunol. Immunother 40: 173-181 (1995)
	GQ	Okarma *et al.*, The AIS cellector: A new technology for stem cell purification, Advances in Bone Marrow Purging and Processing 487-504 (1992)
	GR	Oxholm *et al.*, Cytokine expression in labial salivary glands from patients with primary Sjogrens syndrome, Autoimmunity 12: 185-191 (1992)

EXAMINER	DATE CONSIDERED 5/1/2000

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24731-500E	SERIAL NO. 09/127,138
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GRUENBERG	
	FILING DATE 7/31/98	GROUP 1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

PS	GS	Palliard *et al.*, Simultaneous production of IL-2, Il-4, and IFN-μ by activated human $CD4^+$ and $CD8^+$ I cell clones, J. Immunol. 141: 849-855 (1988)
	GT	Pierrès *et al.*, Triggering CD 28 molecules synergize with CD 2 (T 11.1 and T 11.2)-mediated T cell activation, Eur. J. Immunol. 18: 685-690 (1988)
	GU	Polanski *et al.*, Differentiation of Th2 cells from precursors in ra peripheral blood, (submitted 1996)
	GV	Powrie *et al.*, Regulatory interactions between $CD45RB^{High}$ and $CD45RB^{low}$ $CD4^+$ T cells are important for the balance between protective and pathogenic cell-medicated immunity, J. Exp. Med. 179: 589-600 (1994)
	GW	Puchetti *et al.*, A T_H1-T_H2-like switch in candidiasis: New perspectives for therapy, Trends Microbiol. 3(6): 237-240 (1995)
	GX	Quayle *et al.*, Theumatoid inflammatory T-cell clones express mostly Th-1 but also Th2 and mixed (Th0-like) cytokine patterns, Scand. J. Immunol. 38: 75-82 (1993)
	GY	Reinherz *et al.*, Separation of functional subsets of human T cells by a monoclonal antibody, Proc. Natl. Acad. Sci. USA 76: 4061-4065 (1979)
	GZ	Riddell *et al.*, Principles for adoptive T cell therapy of human viral diseases, Ann. Rev. Immunology 13: 545-586 (1995)
	HA	Riddell *et al.*, Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones, Science 257: 238-241 (1992)
	HB	Riddell *et al.*, CD8+ cytotoxic T cell therapy of cytomegalovirus and HIV infection, Immunology 5: 484-491 (1993)
	HC	Romagnani *et al.*, Regulation of the development of type 2 T-helper cells in allergy, Immunology 6: 838-846 (1994)
	HD	Romagnani *et al.*, HIV can induce a T_H1 to T_H0 shift, and preferentially replicates in $CD4^+$ T-cell clones producing T_H2-type cytokines, 60th Forum in Immunology, 611-617 (1994)
	HE	Romani *et al.*, Proliferating dendritic cell progenitors in human blood, J. Exp. Med. 180: 83-93, (1994).
	HF	Romani *et al.*, Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance, Infection and Immunity 59: 4647-4654 (1991)
	HG	Rosenberg *et al.*, Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N. Engl. J. Med. 313: 1485-1492 (1985)

EXAMINER	DATE CONSIDERED 5/1/2000

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24731-500E	SERIAL NO. 09/127,138
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GRUENBERG	
	FILING DATE 7/31/98	GROUP 1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

PMS	HH	Rosenberg *et al.*, A progress on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, N. Engl. J. Med. 316: 889-897 (1987)
	HI	Rosenberg *et al.*, Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma, N. Engl. J. Med. 319: 1676-1680 (1988)
	HJ	Rutzky *et al.*, Human colon adenocarcinoma cells. III. *In vitro* organoid expression and carcinoembryonic antigen kinetics in hollow fiber culture, J. Natl. Cancer Inst. 63: 85-93 (1979)
	HK	Sacchi *et al.*, Induction of tumor regression in experimental model of human head and neck cancer by human A-Lak cells and IL-2, Int. J. Cancer, 47: 784-791 (1991)
	HL	Salgaller *et al.*, Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated *in vitro* with synthetic peptides, Cancer Res. 55: 4972-4979 (1995)
	HM	Saoudi *et al.*, TH2 activated cells prevent experiential autoimmune unveoretinitis, a TH1-dependent autoimmune disease, Eur. J. Immunol. 23: 3096-3103 (1993)
	HN	Scott *et al.*, The role of T-cell subsets and cytokines in the regulation of infection, Immunology Today, 12: 346-348, (1991).
	HO	Scott, P. *et al.*, "Role of Cytokines and CD4+ T-Cell Subsets in the Regulation of Parasite Immunity and Disease", Immunol. Rev., 112:161-182 (1989)
	HP	Seder *et al.*, Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon μ production and diminishes interleukin 4 inhibition of such priming, Proc. Natl. Acad. Sci. USA 90: 10188-10192 (1993)
	HQ	Sedlmayr *et al.*, Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells, J. Immunotherapy 10: 336-346 (1991)
	HR	Shanafelt *et al.*, Costimulatory signals can selectively modulate cytokine production by subsets of $CD4^+$ T cells, J. Immunol. 154: 1684-1690 (1995).
	HS	Sher *et al.*, Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection, Immunological Rev. 127: 183-204 (1992).
✓	HT	Shimizu *et al.*, Costimulation of proliferative responses of resting $CD4^+$ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin, J. Immunol. 145: 59-67 (1990)

EXAMINER	DATE CONSIDERED 5/1/2000

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24731-500E	SERIAL NO. 09/127,138
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GRUENBERG	
	FILING DATE 7/31/98	GROUP 1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	HU	Simon *et al.*, Divergent T-cell cytokine patterns in inflammatory arthritis, Proc. Natl. Acad. Sci. USA 91: 8562-8566 (1994)
	HV	Spertini *et al.*, Signals delivered via MHC class II molecules synergize with signals delivered via TCR/CD3 to cause proliferation and cytokine gene expression in T cells, J. Immunol. 149: 65-70 (1992)
	HW	Springer *et al.*, Adhesion receptors of the immune system, Nature 346: 425-434 (1990)
	HX	Sugie *et al.*, Stimulation of NK-like YT cells via leukocyte function-associated antigen (LFA)-1, J. Immunol. 154: 1691-1698 (1995)
	HY	Swabb *et al.*, Diffusion and convection in normal and neoplastic tissues, Cancer Res. 34: 2814-2814 (1974)
	HZ	Sznol *et al.*, Adoptive immunotherapy, Cancer Chemotherapy and Biological Responses Modifiers Annual 14: 227-248 (1993)
	IA	Takahashi *et al.*, Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion, Jpn. J. Cancer Res. 86: 861-866 (1995)
	IB	Tamura *et al.*, T cell activation through TCR/-CD3 complex IL-2 production of T cell clones stimulated with anti-CD3 without cross-linkage, J. Immunol. 148: 2370-2377 (1992)
	IC	Tax *et al.*, Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells, Nature 304: 445-447 (1983)
	ID	Thompson *et al.*, Prolonged continuous intravenous infusion interleukin-2 and lumphokine-activated killer-cell therapy for metastatic renal cell carcinoma, J. Clin. Oncol. 10: 960-968 (1992)
	IE	Thygesen *et al.*, Immunity to experimental *Salmonella typhimurium* infections in rats, APMIS 102: 489-494 (1994)
	IF	Torpey, Effects of adoptive immunotherapy with autologous VS8+ T lymphocytes on immunologic parameters: Lymphocyte subsets and cytotoxic, Clinical Immunol. Immunopathol. 68,: 263-272 (1993)
	IG	Toso, J.F. *et al.*, "MAGE-1-Specific Precursor Cytotoxic T-Lymphocytes Present among Tumor-Infiltrating Lymphocytes from a Patient with Breast Cancer: Characterization and Antigen-Specific Activation", Cancer Res., 56:16-20 (1996)
	IH	Turner *et al.*, Human T cells from autoimmune and normal individuals can produce tumor necrosis factor, Eur. J. Immunol. 17: 1807-1814 (1987)

EXAMINER	DATE CONSIDERED 5/1/2001

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24731-500E	SERIAL NO. 09/127,138
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GRUENBERG	
	FILING DATE 7/31/98	GROUP 1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

PBG	II	Tze *et al.*, Long-term survival of adult rat islets of Langerhans in artificial capillary culture units, Diabetes, 26: 185-191 (1977)
	IJ	Urban *et al.*, The importance of Th2 cytokines in protective immunity to nematodes, Immunological Reviews, 127: 205-220 (1992)
	IK	Utsugi *et al.*, Prevention of recurrent diabetes in syngeneic islet-transplanted NOD Mice by transfusion of autoreactive T lymphocytes, Transplantation 57: 1799-1804 (1994)
	IL	Van Lier *et al.*, Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen, J. Immunol. 139: 1589-1596 (1987)
	IM	Van Lunzen *et al.*, Investigations on autologous T-cells for adoptive immunotherapy of AIDS, Cell Activation and Apoptosis in HIV Infection, 6: 57-70 (1995)
	IN	Vandenberghe *et al.*, Immobilized anti-CD5 together with prolonged activation of protein kinase C induce interleukin 2-dependent T cell growth: Evidence for signal transduction through CD5, Eur. J. Immunol. 21: 251-259 (1991)
	IO	Whiteside *et al.*, Generation and characterization of *ex vivo* propagated autologous CD8+ cells used for adoptive immunotherapy of patients infected with human immunodeficiency virus, Blood, 81: 2085-2092 (1993)
	IP	Wolf *et al.*, Bilirubin conjugation by an artificial liver composed of cultured cells and synthetic capillaries, Tran. Amer. Soc. Artif. Int. Organs. 21: 16-27 (1975)
	IQ	Yamamura *et al.*, Defining protective responses to pathogens: Cytokine profiles in leprosy lesions, Science 254: 277-279 (1991)
	IR	Yang *et al.*, *In vitro* priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation, J. Immunol. 155: 3897-3903 (1995)
	IS	Yannelli *et al.*, The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer, Journal of Immunological Methods 139: 1-16 (1991)
↓	IT	Zhang *et al.*, T-cell cytokine responses in human infection with *Mycobacterium tuberculosis*, Infectious Immunology: 3231-3234 (1995)

EXAMINER	DATE CONSIDERED 5/1/2000

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.